Clinical Data raises $27.8 million through common stock public offering

NewsGuard 100/100 Score

Clinical Data, Inc. (NASDAQ: CLDA) today announced that it has raised gross proceeds of approximately $27.8 million through the public offering of 1,945,576 newly issued shares of its common stock at a price of $14.30 per share. All of the shares are being offered by Clinical Data, Inc., which exhausts all remaining shares on its existing shelf registration statement. The underwriters have an option to purchase up to an additional 291,836 shares to cover over-allotments, which, if purchased, would result in total gross proceeds to the Company of approximately $32.0 million. The offering is expected to close no later than June 14, 2010, subject to the satisfaction of customary closing conditions.

BMO Capital Markets Corp. is acting as the sole book running manager, with Wedbush PacGrow Life Sciences and Roth Capital Partners, LLC as co-managers in the offering. The offering is being made pursuant to effective shelf registration statements filed with the Securities and Exchange Commission. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from the Securities and Exchange Commission at http://www.sec.gov, or from BMO Capital Markets Corp. at 3 Times Square, New York, NY 10036, or by calling (212) 885-4039.

Source:

 Clinical Data, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.